In total 15 NSCLC cell lines covering the high-incidence gene abnormalities, including EGFR mutation (L858R, exon 19 deletion, or exon 21 deletion), FGFR1 amplification, KRAS mutation etc., were exposed to small molecule inhibitors targeting enzymes in glucose and glutamine metabolism or fatty acid oxidation (Supplementary Fig. 1a)17. Here, EGFR is linked to non-small cell lung carcinoma.